20Table 20.1 Risk factors and prognostic models for peripheral T‐cell lymphomas...
15 Chapter 21Table 21.1 Clinical activity of US Federal Drug Administration‐approved singl...Table 21.2 Clinical activity of US Federal Drug Administration‐approved singl...Table 21.3 Clinical activity of US Federal Drug Administration‐approved singl...
16 Chapter 22Table 22.1 Risk of bias summary: review authors’ judgments of each risk of bi...Table 22.2 Clinical studies on the use of autologous stem‐cell transplant for...
17 Chapter 23Table 23.1 Results of allogeneic stem‐cell transplantation in patients with r...Table 23.2 Results of allogeneic stem‐cell transplantation in patients affect...
18 Chapter 24Table 24.1 Selected immunotherapy agents in relapsed peripheral T‐cell lympho...
19 Chapter 25Table 25.1 Experiences with new agents in peripheral T‐cell lymphoma.
20 Chapter 26Table 26.1 T cell lymphoma at diagnosis.Table 26.2 Frequency of lymphoma subtypes according to different data sources...Table 26.3 Overall and progression free survival rates for different T‐cell l...Table 26.4 Survival rates and prognostic factors by different subtypes report...Table 26.5 Available data sources.Table 26.6 Frequency of different lymphoma subtypes and outcomes reported in ...
21 Chapter 27Table 27.1 Activity of the new drug combinations in mature T‐cell lymphoma.Table 27.2 Clinical trials presently exploring novel agents in relapsed/refra...
List of Illustrations
1 Chapter 1Figure 1.1 Schematic overview of T‐cell ontogeny and differentiative traject...Figure 1.2 Representative immunohistochemical staining for PD1 (upper left) ...Figure 1.3 The biomass of CD8+ effector T cells is dramatically different be...
2 Chapter 2Figure 2.1 Summary of deregulated signaling pathways in peripheral T‐cell ly...Figure 2.2 Neoplastic T follicular helper cells and their microenvironment i...Figure 2.3 Cellular derivation of T‐cell and NK‐cell lymphomas from the inna...
3 Chapter 3Figure 3.1 Common epigenetic targets in peripheral T‐cell lymphoma. TET = te...Figure 3.2 A simplified schematic of the action of histone deacetylase inhib...
4 Chapter 6Figure 6.1 Angioimmunoblastic T‐cell lymphoma. Lymph node contains a polymor...Figure 6.2 Follicular T‐cell lymphoma. The low‐power view of the lymph node ...Figure 6.3 Anaplastic large‐cell lymphoma, anaplastic lymphoma kinase‐negati...Figure 6.4 Adult T‐cell leukemia/lymphoma. Neoplastic lymphoid cells have pl...Figure 6.5 Enteropathy‐associated T‐cell lymphoma. CD3 stain shows increased...Figure 6.6 Monomorphic epitheliotropic intestinal T‐cell lymphoma. Monotonou...Figure 6.7 Hepatosplenic T‐cell lymphoma. Liver biopsy shows intrasinusoidal...Figure 6.8 Subcutaneous panniculitis‐like T‐cell lymphoma. Atypical lymphoid...
5 Chapter 7Figure 7.1 Representative heatmap of diagnostic signatures used in the molec...Figure 7.2 Stages of T‐cell development and differentiation. T cells origina...Figure 7.3 T‐cell receptor (TCR) activation and downstream signaling cascade...
6 Chapter 9Figure 9.1 Histopathology of angioimmunoblastic T‐cell lymphomas: the archit...
7 Chapter 10Figure 10.1 Systemic anaplastic large‐cell lymphoma (ALCL). (A–D) anaplastic...Figure 10.2 Localized anaplastic large‐cell lymphoma (ALCL). (A)–(D) primary...
8 Chapter 11Figure 11.1 Peripheral blood films of adult T‐cell leukemia/lymphoma. These ...Figure 11.2 Adult T‐cell leukemia/lymphoma (ATLL) subtypes according to Shim...
9 Chapter 12Figure 12.1 Extranodal natural killer (NK)/T‐cell lymphoma. (A) Clinical pre...Figure 12.2 The incidence of extranodal natural killer/T‐cell lymphoma among...Figure 12.3 Summary of the pathways involved in the pathogenesis of extranod...Figure 12.4 Positron emission tomography scan showing adrenal gland localiza...Figure 12.5 Extranasal localization of extranodal natural killer/T‐cell lymp...
10 Chapter 14Figure 14.1 Dysregulated cell signaling pathways in large granular lymphocyt...Figure 14.2 Characteristics of immune cells in large granular lymphocyte leu...
11 Chapter 15Figure 15.1 Dural involvement by peripheral T‐cell lymphoma not otherwise sp...Figure 15.2 (a) Skin manifestations of gamma–delta T cell lymphoma. Lesions ...Figure 15.3 Primary cutaneous gamma–delta T‐cell lymphoma involving deep der...Figure 15.4 Nodal involvement by a primary cutaneous gamma delta T‐cell Lymp...Figure 15.5 Dural involvement by peripheral T‐cell lymphoma, NOS with gamma ...
12 Chapter 16Figure 16.1 Enteropathy‐associated T‐cell lymphoma. (a) A dense infiltrate o...Figure 16.2 Refractory celiac disease (RCD). (a) Duodenal biopsy from a pati...Figure 16.3 Monomorphic epitheliotropic intestinal T‐cell lymphoma. The lami...
13 Chapter 18Figure 18.1 Mycosis fungoides; hypopigmented and erythematous patches on the...Figure 18.2 Mycosis fungoides with poikilodermatous features.Figure 18.3 Folliculotropic mycosis fungoides; indurated plaques and tumors ...Figure 18.4 Sézary syndrome; diffuse erythroderma with scaling and leonine f...Figure 18.5 Subcutaneous panniculitis‐like T‐cell lymphoma; indurated erythe...Figure 18.6 Histopathologic changes of early mycosis fungoides. The epidermi...Figure 18.7 Immunophenotypic changes in mycosis fungoides. The lymphoid popu...Figure 18.8 Mycosis fungoides with large‐cell transformation. In this biopsy...Figure 18.9 Histopathologic changes of folliculotropic mycosis fungoides. A ...Figure 18.10 Histopathologic changes in Sézary syndrome. The infiltrate is m...Figure 18.11 Histopathologic changes in aggressive epidermotropic CD8+ T‐cel...Figure 18.12 Histopathologic changes in cutaneous CD4+ small to medium T‐cel...Figure 18.13 Immunophenotypic findings in cutaneous CD4+ small to medium T‐c...Figure 18.14 Treatment of patients with mycosis fungoides (Stages I–III).Figure 18.15 Treatment of patients with mycosis fungoides (Stage IV).
14 Chapter 19Figure 19.1 Histopathological findings on lymph node biopsy of systemic Epst...Figure 19.2 Histopathological findings on lymph node biopsy of systemic Epst...
15 Chapter 20Figure 20.1 Overall survival for patients with aggressive peripheral T‐cell ...Figure 20.2 Overall survival for the intention‐to‐treat population. The haza...
16 Chapter 22Figure 22.1 The impact of time. Survival curves of patients based on time pe...Figure 22.2 Survival curve of patients who received novel therapies compared...Figure 22.3 Progression‐free survival stratified by consolidative strategy. ...Figure 22.4 Meta‐analysis of the hazard ratios of overall survival in patien...
17 Chapter 26Figure 26.1 (A) Overall survival of patients with the common subtypes of per...Figure 26.2 Five‐year survival rates in different histological subtypes from...
18 Chapter 28Figure 28.1 Organizational structure of the the Global T‐cell Lymphoma Conso...Figure 28.2 Clinical trial concept evaluation.Figure 28.3 Safety reporting for the Global T‐cell Lymphoma Consortium (FDA,...
Guide
1 Cover
2 Table